Precision BioSciences (NASDAQ:DTIL) Trading 4.9% Higher – Time to Buy?

Precision BioSciences, Inc. (NASDAQ:DTIL)’s share price was up 4.9% during mid-day trading on Friday . The company traded as high as $5.44 and last traded at $5.36. Approximately 90,196 shares traded hands during trading, a decline of 63% from the average daily volume of 246,354 shares. The stock had previously closed at $5.11.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Precision BioSciences presently has a consensus rating of “Hold” and a consensus price target of $47.00.

Precision BioSciences Trading Up 4.9%

The business has a 50 day moving average of $6.02 and a two-hundred day moving average of $5.21. The firm has a market capitalization of $71.07 million, a price-to-earnings ratio of -0.64 and a beta of 1.79. The company has a debt-to-equity ratio of 1.35, a quick ratio of 3.45 and a current ratio of 3.45.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.31) by ($1.53). Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $5.40 million. During the same quarter in the prior year, the firm earned ($2.25) EPS. Equities analysts predict that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Lynx1 Capital Management LP increased its position in shares of Precision BioSciences by 0.6% during the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after acquiring an additional 6,545 shares in the last quarter. Vanguard Group Inc. boosted its stake in Precision BioSciences by 21.5% during the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after purchasing an additional 87,242 shares during the last quarter. Corient Private Wealth LLC acquired a new position in Precision BioSciences during the 2nd quarter valued at about $425,000. Two Sigma Investments LP increased its holdings in Precision BioSciences by 407.8% during the 3rd quarter. Two Sigma Investments LP now owns 83,092 shares of the company’s stock worth $459,000 after purchasing an additional 66,729 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Precision BioSciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after purchasing an additional 4,025 shares during the last quarter. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.